



AIRQ® EHR TIP SHEET

**INSTRUCTIONS TO INTEGRATE
THE ASTHMA IMPAIRMENT AND
RISK QUESTIONNAIRE (AIRQ®)
IN THE CERNER® ELECTRONIC
HEALTH RECORD (EHR) SYSTEM**

TABLE OF CONTENTS

OVERVIEW AND LIMITATIONS.....3

ABOUT THE AIRQ®4

AIRQ® INFORMATION FOR HEALTH CARE PROVIDERS 6

 AIRQ® INDICATIONS.....6

 THE AIRQ® IS NOT INTENDED TO:.....6

 HEALTH CARE PROVIDER INSTRUCTIONS FOR USE6

 INFORMATION ON THE VALIDATION AND INTERPRETATION OF AIRQ®7

CERNER BUILD GUIDE 8

 ENGLISH VERSION.....8

 SPANISH VERSION..... 12

IMPLEMENTING THE FOLLOW-UP AIRQ®16

NOTES17

OVERVIEW AND LIMITATIONS OF INTEGRATING THE AIRQ® INTO THE CERNER® EHR SYSTEM

The AIRQ® is a patient assessment tool intended to help identify patients with asthma 12 years and older whose health may be at risk because of uncontrolled asthma. These instructions can only be used to integrate the AIRQ® in the Cerner EHR system and are not appropriate for other health conditions or EHR systems.

The processes outlined in this resource are variable, and not all steps will apply to every health system. Any steps or settings that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to your EHR system's point of contact. The organization is solely responsible for implementing, testing, monitoring, and ongoing operation of any EHR tools. Please note, no modifications of the AIRQ® questions or their sequencing can be made.

Reach out to your licensing representative at RWS to obtain a free* license to use AIRQ® in your clinic, practice, or health system. Please send an email message to astrazeneca@rws.com to initiate the licensing process. Include the best contacts on your team and the purpose for which you will be using the tool (eg, "clinical assessment of patients with asthma" or "quality improvement or research study") as long as the use of the tool remains in line with intended use.

The Cerner Build Guide section describes how to integrate the AIRQ® into the EHR. The instructions are not intended to replace your health system's processes or protocols, nor is this guide intended to imply that AIRQ® should be used to determine management recommendations. Any decision related to patient care should be made by a patient's health care provider in consultation with the patient.

To integrate the AIRQ®, follow these 3 steps:

1. Secure licensing* from RWS by emailing a request to astrazeneca@rws.com
2. Integrate the English and Spanish versions of the AIRQ® as is appropriate for your system. You may also reach out to RWS for options for securing additional AIRQ® translations
3. Release to the production environment, and provide training and/or an EHR update to end users

*Licenses for use of the US English and US Spanish versions of AIRQ® with patients in a clinical practice, academic setting, or health care system are **free in perpetuity**.

ABOUT THE AIRQ®

The AIRQ® can be found at www.airqscore.com, where PDF and digital versions can be accessed and information on AIRQ® indications and intended use can be obtained.

There are 2 versions of the AIRQ® available for implementation:

AIRQ®: Taken by the patient once every 12 months

Follow-up AIRQ®: Taken by the patient for an HCP encounter occurring between annual visits

The instructions in this build guide are written specifically for implementing the AIRQ®. Guidance around adapting these instructions for implementing the Follow-up AIRQ® are found toward the end of this document.


The Asthma Impairment and Risk Questionnaire (AIRQ®) contains 2 key sections:

Section 1: The questions

- Each question is individually scored and equally weighted (Yes equals 1 point, No equals zero points)

Section 2: The score and interpretation

- The number of yes responses to each of the 10 individual questions is summed to generate the total AIRQ® score
- The interpretation of the total AIRQ® score relative to asthma control is pictured below in the graphic



Note: As asthma control worsens, the chance of an asthma attack increases.¹

When integrating the AIRQ® into the EHR, potential options for how a patient could access the results include:

Option 1: Upon completion of the 10 questions, the patient will be able to view their Total Score interpretation graphics. This option will give the patient the opportunity to review their results in advance and help them engage in a shared-decision conversation with their health care provider prior to the actual clinical encounter

Option 2: Upon completion of the 10 questions, the patient cannot see their Total Score interpretation graphics (the total AIRQ® score is withheld until the health care provider or their staff can discuss it with the patient)

Both options are included in the build instructions. Before implementing the AIRQ® in the EHR, ascertain if Option 1 is feasible.

¹Global Strategy for Asthma Management and Prevention: ©2021 Global Initiative for Asthma

Printable Version of the AIRQ® in English

AIRQ® (Asthma Impairment and Risk Questionnaire)



For use by health care providers with their patients 12 years and older who have been diagnosed with asthma. AIRQ® is intended to be part of an asthma clinic visit.

Please answer all of the questions below.

In the **past 2 weeks**, has coughing, wheezing, shortness of breath, or chest tightness:

1. Bothered you during the day on **more than 4 days**? Yes No
2. Woke you up from sleep **more than 1 time**? Yes No
3. Limited the activities you want to do **every day**? Yes No
4. Caused you to use your rescue inhaler or nebulizer **every day**? Yes No



Please see all prescribing information for all products.

In the **past 2 weeks**:

5. Did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma? Yes No
6. Did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise? Yes No
7. Did you feel that it was difficult to control your asthma? Yes No

In the **past 12 months**, has coughing, wheezing, shortness of breath, or chest tightness:

8. Caused you to take steroid pills or shots, such as prednisone or Medrol**?
9. Caused you to go to the emergency room or have unplanned visits to a health care provider?
10. Caused you to stay in the hospital overnight?

Total YES Answers

What Does My AIRQ® Score Mean?

The AIRQ® is meant to help your health care providers talk with you about your asthma control. The AIRQ® does not diagnose asthma. Whatever your AIRQ® score (total YES answers), it is important for your health care team to discuss the number and answers to each of the questions with you. All patients with asthma, even those who may be well-controlled, can have an asthma attack. As asthma control worsens, the chance of an asthma attack increases.¹ Only your medical provider can decide how best to assess and treat your asthma.



*Medrol® (Pfizer, Inc.) or methylprednisolone

The trademarks depicted above are the property of their respective owners.

¹Global Strategy for Asthma Management and Prevention: ©2021 Global Initiative for Asthma

©2022 AstraZeneca. All rights reserved. US-61954 Last Updated 3/22

AIRQ® is a registered trademark of AstraZeneca.

Printable Version of the AIRQ® in Spanish



Cuestionario sobre la afectación y el riesgo en el asma (AIRQ™)

Para uso de los proveedores de atención médica con sus pacientes mayores de 12 años que hayan sido diagnosticados de asma. El AIRQ™ está diseñado para formar parte de una visita a una clínica de asma.

Por favor, responda todas las preguntas a continuación.

En las **últimas dos semanas**, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:

1. ¿Le molestaron en el transcurso del día durante **más de cuatro días**? Sí No
2. ¿Lo despertaron **más de una vez**? Sí No
3. ¿Limitaron las actividades que desea realizar **todos los días**? Sí No
4. ¿Hicieron que tuviera que usar su inhalador de rescate o nebulizador **todos los días**? Sí No



Por favor, consulte la ficha técnica completa de todos los productos.

En las **últimas dos semanas**:

5. ¿Tuvo que limitar sus actividades sociales (como visitar a amigos/parientes o jugar con mascotas/niños) debido a su asma? Sí No
6. ¿La tos, la sibilancia, la dificultad para respirar o la presión en el pecho limitaron su capacidad de hacer ejercicio? Sí No
7. ¿Sintió que era difícil controlar su asma? Sí No


En los **últimos 12 meses**, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:

8. ¿Hicieron que tuviera que usar pastillas o inyecciones de corticosteroides, como prednisone o Medrol**?
9. ¿Hicieron que tuviera que ir a una sala de emergencias o consultas no planificadas con un proveedor de atención médica?
10. ¿Hicieron que tuviera que permanecer en el hospital durante la noche?

Total de respuestas "Sí"

¿Qué significa mi puntuación AIRQ™?

El AIRQ™ tiene como objetivo ayudar a sus proveedores de atención médica a hablar con usted sobre el control de su asma. El AIRQ™ no diagnostica el asma. Cualquiera que sea su puntuación de AIRQ™ (total de respuestas afirmativas), es importante que su equipo de atención médica converse con usted acerca del número que obtenga y las respuestas a cada una de las preguntas. Todos los pacientes con asma, incluso aquellos que podrían estar bien controlados, pueden tener una crisis asmática. A medida que el control del asma empeora, la probabilidad de sufrir una crisis asmática aumenta.¹ Solamente su proveedor médico puede decidir la mejor manera de evaluar y tratar su asma.



*Medrol® (Pfizer, Inc.) o metilprednisolona

Las marcas registradas que se muestran arriba son propiedad de sus respectivos dueños.

¹Estrategia mundial para el tratamiento y la prevención del asma: ©2020 Iniciativa mundial para el asma

©2020 AstraZeneca. Todos los derechos reservados. US-44917 10/20

AIRQ™ es una marca registrada de AstraZeneca.

AIRQ® INFORMATION FOR HEALTH CARE PROVIDERS

AIRQ® Indications

The AIRQ® is a patient assessment tool intended to help identify patients 12 years of age and older whose health may be at risk because of uncontrolled asthma. This assessment is based on a series of patient-facing questions about asthma medications, respiratory symptoms, and utilization of health care resources. Depending on the patient's responses to these questions, the patient will receive a score reflecting their level of asthma control. After completion of the AIRQ®, the patient and health care provider should discuss the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control and form a treatment plan.

The AIRQ® Is Not Intended To:

- Diagnose asthma
- Replace the advice or treatment of a health care provider
- Direct specific actions to treat, mitigate, or improve asthma
- Collect or store any laboratory values or lung function test values

Health Care Provider Instructions for Use

1. Provide your patient with the AIRQ® during or immediately prior to their appointment.
2. Examine the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control.
3. Discuss responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control with your patient.
4. Determine a treatment plan with your patient based on the information you've learned during your discussion and clinical assessment of the patient, and through responses to the AIRQ® questions.

Information on the Validation and Interpretation of AIRQ®

1. AIRQ® is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items.
2. The AIRQ® was validated against a standard of ACT™ score (impairment) + prior-year, chart-documented exacerbations (risk) in 442 patients 12 years of age and older who were previously diagnosed with asthma.
3. Multivariable logistic regression analyses were used to determine questions with the greatest validity in discriminating between patients of varying levels of control.
4. A total of 10 questions were identified for inclusion in the AIRQ®.
5. The AIRQ® performed well with respect to the ACT™ + exacerbations standard in identifying well-controlled vs not well-/very poorly controlled and well-/not well-controlled vs very poorly controlled asthma, with area under the ROC (receiver operating characteristic) curves of 0.94 and 0.93, respectively.
6. The combination of selected AIRQ® items and cut points of control demonstrated a sensitivity of 0.90 to identify patients whose asthma was well-controlled (cut point of ≥ 2), and a specificity of 0.96 to determine patients whose asthma was very poorly controlled (cut point of ≥ 5).
7. For further information on the development and cross-sectional validation of the AIRQ®, please refer to Murphy KR, et al. *J Allergy Clin Immunol Pract.* 2020;8(7):2263-2274.e5. and Murphy KR, et al. *J Allergy Clin Immunol Pract.* 2021;9(1):603.

CERNER BUILD GUIDE


English Version

Administrator privileges are usually required to access this functionality.

Step 1: Create DTAs for the AIRQ®

The first step is to confirm if discrete task assays (DTAs) are available or to create new DTAs if none are available. Follow the steps below to create new DTAs:

1. Launch DCPTools.exe to access the DTA Wizard
2. Click Clear in the DTA Wizard
3. Create 11 new DTAs (one for each of the questions in the AIRQ® and one for the AIRQ® score) with the same Unique Mnemonic and Description based on the organization's naming conventions. Set the Result Type to Alpha and add 2 rows in the Alpha Details tab (Yes and No). In the Result field, set the Yes answer to 1 and the No answer to 0. Press OK once completed (see the chart on page 9 for DTAs)
4. Associate the Event Code by clicking on the binoculars icon. Click Apply to complete the DTA creation process



English Version (cont'd)

DTA Description / DTA Mnemonic	DTA Result Type	Alpha Responses	Alpha Result Value
1. Bothered you during the day on more than 4 days ?	Alpha	Yes	1
		No	0
2. Woke you up from sleep more than 1 time ?	Alpha	Yes	1
		No	0
3. Limited the activities you want to do every day ?	Alpha	Yes	1
		No	0
4. Caused you to use your rescue inhaler or nebulizer every day ?	Alpha	Yes	1
		No	0
5. Did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma?	Alpha	Yes	1
		No	0
6. Did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise?	Alpha	Yes	1
		No	0
7. Did you feel that it was difficult to control your asthma?	Alpha	Yes	1
		No	0
8. Caused you to take steroid pills or shots, such as prednisone or Medrol®?	Alpha	Yes	1
		No	0
9. Caused you to go to the emergency room or have unplanned visits to a health care provider?	Alpha	Yes	1
		No	0
10. Caused you to stay in the hospital overnight?	Alpha	Yes	1
		No	0
Total YES Answers	Calculation	Equation (row 1 + row 2 + ... + row 10)	

English Version (cont'd)

Step 2: Create the AIRQ® PowerForm

1. Launch DCPTools.exe to access the PowerForm tool
2. Create a Form Section by clicking Section > New
3. Enter "AIRQ®" as the Section Name and Section Display and click OK
4. Drag a label from the toolbox in the section under the AIRQ® header
5. Add a header in the form and label it:
"For use by health care providers with their patients 12 years and older who have been diagnosed with asthma. AIRQ® is intended to be part of an asthma clinic visit. Please answer all of the questions below. For more detailed instructions, please click here: <http://patientifu.digitalairq.com>"
6. Drag a label from the toolbox in the section under the AIRQ® use recommendation (Step 5)
7. Add a header in the form and label it:
"In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness:"
8. Drag an Alpha Box for each of the first 4 DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 1, 2, 3, and 4 of the AIRQ®)
9. Right-click the Alpha Boxes and associate them with the DTAs
10. Drag a label from the toolbox in the section under the first 4 questions
11. Right-click the blank label and from the input controls, click Image. Select the image from here: <http://english.inhalers.airqimages.com/> (the image displays rescue inhalers and nebulizers to help the patient with answering question 4)
12. Add a header in the form and label it:
"In the past 2 weeks:"
13. Drag an Alpha Box for each of the next 3 DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 5, 6, and 7 of the AIRQ®)
14. Right-click the Alpha Boxes and associate them with the DTAs
15. Add a header in the form and label it:
"In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness:"
16. Drag an Alpha Box for each of the DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 8, 9, and 10 of the AIRQ®)
17. Right-click the Alpha Boxes and associate them with the DTAs

English Version (cont'd)

The health system has a choice of how to complete the AIRQ®:

- **Option 1:** Upon completion of the 10 questions, the patient will be able to view their Total Score interpretation graphics. This option will give the patient the opportunity to review their results in advance and help them engage in a shared-decision conversation with their health care provider prior to the actual clinical encounter



Complete Steps 18–25; the result can be displayed within the same section as Steps 1–17

- **Option 2:** Upon completion of the 10 questions, the patient cannot see their Total Score Interpretation graphics (the total AIRQ® score is withheld until the health care provider or their staff can discuss it with the patient)



Prior to completing Steps 18–25, create a new section on the form. Enter “Result is available below so it can be discussed with the patient by their health care provider (or their staff)”

To see the score, scroll down to the next section where all result information is available

18. Add a header in the form and label it:
“Total YES Answers”
19. Drag a Numeric Box for Total YES Answers score, right-click it, and associate it with the DTAs for the Total YES Answers score
20. Add a header in the form and label it:
“What Does My AIRQ® Score Mean?”
21. Drag a label from the toolbox in the section under the Section 2 Score. Enter:
“The AIRQ® is meant to help your health care providers talk with you about your asthma control. The AIRQ® does not diagnose asthma. Whatever your AIRQ® score (total YES answers), it is important for your health care team to discuss the number and answers to each of the questions with you. All patients with asthma, even those who may be well-controlled, can have an asthma attack. As asthma control worsens, the chance of an asthma attack increases.¹ Only your medical provider can decide how best to assess and treat your asthma.
*Medrol® (Pfizer, Inc.) or methylprednisolone
The trademarks depicted above are the property of their respective owners.
¹Global Strategy for Asthma Management and Prevention ©2021 Global Initiative for Asthma”
22. Drag a label from the toolbox in the section under the header labeled “What Does My AIRQ® Score Mean?”
23. Right-click the blank label and from the input controls, click Image. Select the image from here: <http://english.stick.airqimages.com/> (the image displays the scale of the AIRQ® scores)
24. Create a new form to contain the sections created above and enter “Total YES Answers” for the name
25. Plug the sections in the new form and click File > Save

Spanish Version

Administrator privileges are usually required to access this functionality.

Step 1: Create DTAs for the AIRQ®

The first step is to confirm if discrete task assays (DTAs) are available or to create new DTAs if none are available. Follow the steps below to create new DTAs:

1. Launch DCPTools.exe to access the DTA Wizard
2. Click Clear in the DTA Wizard
3. Create 11 new DTAs (one for each of the questions in the AIRQ® and one for the AIRQ® score) with the same Unique Mnemonic and Description based on the organization's naming conventions. Set the Result Type to Alpha and add 2 rows in the Alpha Details tab (Sí and No). In the Result field, set the Sí answer to 1 and the No answer to 0. Press OK once completed (see the chart on page 13 for the DTAs)
4. Associate the Event Code by clicking on the binoculars icon. Click Apply to complete the DTA creation process

Spanish Version (cont'd)

DTA Description / DTA Mnemonic	DTA Result Type	Alpha Responses	Alpha Result Value
1. ¿Le molestaron en el transcurso del día durante más de cuatro días ?	Alpha	Sí	1
		No	0
2. ¿Lo despertaron más de una vez ?	Alpha	Sí	1
		No	0
3. ¿Limitaron las actividades que desea realizar todos los días ?	Alpha	Sí	1
		No	0
4. ¿Hicieron que tuviera que usar su inhalador de rescate o nebulizador todos los días ?	Alpha	Sí	1
		No	0
5. ¿Tuvo que limitar sus actividades sociales (como visitar a amigos/parientes o jugar con mascotas/niños) debido a su asma?	Alpha	Sí	1
		No	0
6. ¿La tos, la sibilancia, la dificultad para respirar o la presión en el pecho limitaron su capacidad de hacer ejercicio?	Alpha	Sí	1
		No	0
7. ¿Sintió que era difícil controlar su asma?	Alpha	Sí	1
		No	0
8. ¿Hicieron que tuviera que usar pastillas o inyecciones de corticosteroides, como prednisona o Medrol®*?	Alpha	Sí	1
		No	0
9. ¿Hicieron que tuviera que ir a una sala de emergencias o consultas no planificadas con un proveedor de atención médica?	Alpha	Sí	1
		No	0
10. ¿Hicieron que tuviera que permanecer en el hospital durante la noche?	Alpha	Sí	1
		No	0
Total de respuestas “Sí”	Calculation	Equation (row 1 + row 2 + ... + row 10)	

Spanish Version (cont'd)

Step 2: Create the AIRQ® PowerForm

1. Launch DCPTools.exe to access the PowerForm tool
2. Create a Form Section by clicking Section > New
3. Enter "AIRQ®" as the Section Name and Section Display and click OK
4. Drag a label from the toolbox in the section under the AIRQ® header
5. Add a header in the form and label it:
*"Para uso de los proveedores de atención médica con sus pacientes mayores de 12 años que hayan sido diagnosticados de asma. El AIRQ® está diseñado para formar parte de una visita a una clínica de asma.
Por favor, responda todas las preguntas a continuación. Para mas detalles sobre las instrucciones, por favor oprima aqui: <http://es.patientifu.digitalairq.com>"*
6. Drag a label from the toolbox in the section under the AIRQ® use recommendation (Step 5)
7. Add a header in the form and label it:
"En las últimas dos semanas, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:"
8. Drag an Alpha Box for each of the first 4 DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 1, 2, 3, and 4 of the AIRQ®)
9. Right-click the Alpha Boxes and associate them with the DTAs
10. Drag a label from the toolbox in the section under the first 4 questions
11. Right-click the blank label and from the input controls, click Image. Select the image from here: <http://spanish.inhalers.airqimages.com/> (the image displays rescue inhalers and nebulizers to help the patient with answering question 4)
12. Add a header in the form and label it:
"En las últimas dos semanas:"
13. Drag an Alpha Box for each of the next 3 DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 5, 6, and 7 of the AIRQ®)
14. Right-click the Alpha Boxes and associate them with the DTAs
15. Add a header in the form and label it:
"En los últimos 12 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho:"
16. Drag an Alpha Box for each of the DTAs created in "Step 1: Create DTAs for the AIRQ®" (questions 8, 9, and 10 of the AIRQ®)
17. Right-click the Alpha Boxes and associate them with the DTAs

Spanish Version (cont'd)

The health system has a choice of how to complete the AIRQ®:

- **Option 1:** Upon completion of the 10 questions, the patient will be able to view their Total Score interpretation graphics. This option will give the patient the opportunity to review their results in advance and help them engage in a shared-decision conversation with their health care provider prior to the actual clinical encounter



Complete Steps 18–25; the result can be displayed within the same section as Steps 1–17

- **Option 2:** Upon completion of the 10 questions, the patient cannot see their Total Score Interpretation graphics (the total AIRQ® score is withheld until the health care provider or their staff can discuss it with the patient)



Prior to completing Steps 18–25, create a new section on the form. Enter “Result is available below so it can be discussed with the patient by their health care provider (or their staff)”

To see the score, scroll down to the next section where all result information is available

18. Add a header in the form and label it:
“Total de respuestas ‘Sí’”
19. Drag a Numeric Box for Total de respuestas “Sí” score, right-click it, and associate it with the DTA for the Total de respuestas “Sí” score
20. Add a header in the form and label it:
“¿Qué significa mi puntuación AIRQ®?”
21. Drag a label from the toolbox in the section under the Section 2 Score. Enter:
“El AIRQ® tiene como objetivo ayudar a sus proveedores de atención médica a hablar con usted sobre el control de su asma. El AIRQ® no diagnostica el asma. Cualquiera que sea su puntuación de AIRQ® (total de respuestas afirmativas), es importante que su equipo de atención médica converse con usted acerca del número que obtenga y las respuestas a cada una de las preguntas. Todos los pacientes con asma, incluso aquellos que podrían estar bien controlados, pueden tener una crisis asmática. A medida que el control del asma empeora, la probabilidad de sufrir una crisis asmática aumenta.¹ Solamente su proveedor médico puede decidir la mejor manera de evaluar y tratar su asma.
*Medrol® (Pfizer, Inc.) o metilprednisolona
Las marcas registradas que se muestran arriba son propiedad de sus respectivos dueños.
¹Estrategia mundial para el tratamiento y la prevención del asma: ©2021 Iniciativa mundial para el asma”
22. Drag a label from the toolbox in the section under the header labeled “¿Qué significa mi puntuación AIRQ®?”
23. Right-click the blank label and from the input controls, click Image. Select the image from here: <http://spanish.stick.airqimages.com/> (the image displays the scale of the AIRQ® scores)
24. Create a new form to contain the sections created above and enter “Total de respuestas ‘Sí’” for the name
25. Plug the sections in the new form and click File > Save

IMPLEMENTING THE FOLLOW-UP AIRQ®

It is recommended that patients complete the AIRQ® once every 12 months. If you wish for patients to complete the AIRQ® for HCP encounters in the interim, patients should complete the Follow-up AIRQ®.

The Follow-up AIRQ® is almost identical to the AIRQ®; the sole exception is the stem language appearing immediately before question 8:

AIRQ®	Follow-up AIRQ®
In the <u>past 12 months</u> , has coughing, wheezing...	In the <u>past 3 months</u> , has coughing, wheezing...

If you wish to administer the Follow-up AIRQ® in your practice, you will need to implement a second version of the AIRQ® in your system, observing the sole difference in language as noted above.

To execute, update the header added in Step 15 of the PowerForm build guide to the following (the sole difference in language is highlighted for your illustration):

English Version: “In the past 3 months, has coughing, wheezing, shortness of breath, or chest tightness.”

Spanish Version: “En los últimos 3 meses, la tos, la sibilancia, la dificultad para respirar o la presión en el pecho.”

It would be up to your staff to ensure that the patient is directed to the appropriate version of the AIRQ®, whether they need to complete the AIRQ® for their annual visit or the Follow-up AIRQ® for an interim encounter.

NOTES

- The Customer (eg, physician, medical group, IDN) shall be solely responsible for implementation, testing, and monitoring of the instructions to ensure proper orientation in each Customer's EHR system
- Capabilities, functionality, and setup (customization) for each individual EHR system vary. AstraZeneca shall not be responsible for revising the implementation instructions it provides to any Customer in the event that Customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by AstraZeneca
- While AstraZeneca tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems and AstraZeneca shall have no liability thereto
- While EHRs may assist providers in identifying appropriate patients for consideration of assessment and treatment, the decision and action should ultimately be decided by a provider in consultation with the patient, after a review of the patient's records to determine eligibility, and AstraZeneca shall have no liability thereto
- The instructions have not been designed for and are not tools and/or solutions for meeting Advancing Care Information and/or any other quality/accreditation requirement
- All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of AstraZeneca and/or its affiliates
- Please provide any feedback on the instructions or use of the AIRQ® to precisionfeedback@astrazeneca.com

Cerner® is a registered trademark of Cerner Corporation.

Certification

This is to certify that RWS Life Sciences, Inc. has performed the following procedures on the
90047_AZ_US-44918_Asthma Desktop_V4_Spanish-US
[RWS Life Sciences Job #: 230710A]:

Source filename: 90047_AZ_US-33841_Asthma Desktop_V4
Target filename: 90047_AZ_US-44918_Asthma Desktop_V4_Spanish-US
English Asset: US-33841 into Spanish Asset: US-44918
Document(s)
English (US) translated to Spanish (US)

- Two independent forward translations
- One harmonized forward translation
- One independent back-translation
- Reconciliation of back-translation and harmonized translation
- Review of back-translation by Survey Research Analyst
- Review of harmonized translation by on-site sponsor representative
- Cognitive debriefing with five patients with asthma in the United States
- Desktop publishing of validated translation
- Proofreading of validated translation

These documents were translated from English to Spanish and prepared by a team of translators and interviewers who are fully bilingual in both Spanish for the United States and English. All procedures were performed in accordance with current industry standards and FDA guidance.

Authorized Signature:



Digitally signed by
RWS Life Sciences
Date: 2020.11.20
14:12:12 -06'00'